Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0242339 (dyslipidemia)
 13,927 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Diabetic macular edema (DME) is the most common cause of vision loss in patients with type 1 and type 2 diabetes. Glycemic control, hypertension, and dyslipidemia are known to be important risks factors for DME. In addition, nephropathy, anemia, sleep apnea, glitazone usage, and pregnancy are also important modifiable risk factors. It is important for physicians of different subspecialties to work together and understand multiple aspects of DME and diabetic healthcare.
 ...
PMID:Risk factors associated with diabetic macular edema. 2338 Jan 34

Diabetic macular edema (DME), a serious eye complication caused primarily by hyperglycemia, is one of the major causes of blindness. DME, which is characterized by cystic retinal thickening or lipid deposition, is prone to relapse after successful treatment. DME is a complex pathological process caused by multiple factors, including breakdown of the inner and outer blood-retinal barriers, oxidative stress, and elevated levels of vascular endothelial growth factor which have been demonstrated in both preclinical and clinical studies. Starling's law theory explains many of the features of DME. Early detection and treatment of DME can prevent vision loss. Current effective interventions for DME include treatment of systemic risk factors, such as elevated blood glucose, blood pressure and dyslipidemia. Ophthalmic treatments include laser photocoagulation, surgery and intraocular pharmacotherapy. New drugs, which are given by intraocular injection, have emerged in recent years to become first line treatment for DME that affects the central macula with loss of vision. Laser photocoagulation is still the gold standard of treatment for DME which does not involve the central macular. This review outlines these new treatments with particular emphasis on the optimal timing of how they are given.
...
PMID:Diabetic macular edema: new concepts in patho-physiology and treatment. 2495 34